4 assets in Malignant Peritoneal Mesothelioma

Therapeutic assets addressing Malignant Peritoneal Mesothelioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Malignant Peritoneal Mesothelioma	M.D. Anderson Cancer Center	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Malignant Peritoneal Mesothelioma	National Cancer Institute (NCI)	P1/2	CCC (48)
Methoxyamine Malignant Peritoneal Mesothelioma	National Cancer Institute (NCI)	P1/2	CCC (48)
ct-95 Malignant Peritoneal Mesothelioma	Context Therapeutics Inc.	P1	CC (43)